DIFFICULTIES OF PREOPERATIVE DIFFERENTIAL DIAGNOSIS OF UTERINE LEIOMYOSARCOMA AND LEIOMYOMA: CLINICAL CASE REPORT
Main Article Content
Abstract
Uterine leiomyoma (LM) is the most common benign tumor of the uterus. In some cases, LM can be difficult to distinguish from malignant analogues – smooth muscle tumors with unknown malignant potential and leiomyosarcoma (LMS). Special difficulties in the differential diagnosis between LM and LMZ arise with fatty or myxoid degeneration of myomatous nodes. Leiomyosarcomas account for about 70% of all uterine sarcomas and cause a significant proportion of deaths from uterine cancer. In appearance, LMS is a formation in the myometrium and therefore most often mimics benign uterine leiomyoma (LM). The case presented by us illustrates the importance of preoperative diagnosis of benign and malignant uterine formations for choosing an adequate management strategy for such patients, as well as determining the expediency and scope of surgical treatment.
Keywords
Article Details
Information about financing and conflict of interests
The authors declare that they have no apparent or potential conflicts of interest related to the publication of this article.
This work is licensed under a Creative Commons Attribution 4.0 License.
How to Cite
References
1. Tsuyoshi H, Yoshida Y. Molecular biomarkers for uterine leiomyosarcoma and endometrial stromal sarcoma. Cancer Sci. 2018; 109(6): 1743-1752. doi: 10.1111/cas.13613
2. Yang Q, Madueke-Laveaux OS, Cun H, Wlodarczyk M, Garcia N, Carvalho KC, Al-Hendy A. Comprehensive Review of Uterine Leiomyosarcoma: Pathogenesis, Diagnosis, Prognosis, and Targeted Therapy. Cells. 2024; 13(13): 1106. doi: 10.3390/cells13131106
3. Santos P, Cunha TM. Uterine sarcomas: clinical presentation and MRI features. Diagn Interv Radiol. 2015; 21(1): 4-9. doi: 10.5152/dir.2014.14053
4. Coffin PH, Ascher S, Spies J. The risk of uterine malignancy in a population being evaluated for uterine fibroid embolization. J Comput Assist Tomogr. 2020; 44(6): 893-900. doi: 10.1097/RCT.0000000000001104
5. Hindman N, Kang S, Fournier L, Lakhman Y, Nougaret S, Reinhold C, et al. MRI Evaluation of Uterine Masses for Risk of Leiomyosarcoma: A Consensus Statement. Radiology. 2023; 306(2): e211658. doi: 10.1148/radiol.211658
6. Sun S, Bonaffini PA, Nougaret S, Fournier L, Dohan A, Chong J, et al. How to differentiate uterine leiomyosarcoma from leiomyoma with imaging. Diagn Interv Imaging. 2019; 100(10): 619-634. doi: 10.1016/j.diii.2019.07.007
7. Exacoustos C, Romanini ME, Amadio A, Amoroso C, Szabolcs B, Zupi E, Arduini D. Can gray-scale and color Doppler sonography differentiate between uterine leiomyosarcoma and leiomyoma? J Clin Ultrasound. 2007; 35(8): 449-457. doi: 10.1002/jcu.20386
8. Cabezas N, López-Picazo A, Diaz P, Valero B, Rodriguez MJ, Redondo A, et al. How Frequently Benign Uterine Myomas Appear Suspicious for Sarcoma as Assessed by Transvaginal Ultrasound? Diagnostics (Basel). 2023; 13(3): 501. doi: 10.3390/diagnostics13030501
9. Bura V, Pintican RM, David RE, Addley HC, Smith J, Jimenez-Linan M, et al. MRI findings in-between leiomyoma and leiomyosarcoma: a Rad-Path correlation of degenerated leiomyomas and variants. Br J Radiol. 2021; 94(1125): 20210283. doi: 10.1259/bjr.20210283
10. DeMulder D, Ascher SM. Uterine Leiomyosarcoma: Can MRI Differentiate Leiomyosarcoma From Benign Leiomyoma Before Treatment? AJR Am J Roentgenol. 2018; 211(6): 1405-1415. doi: 10.2214/AJR.17.19234
11. Tong A, Kang SK, Huang C, Huang K, Slevin A, Hindman N. MRI screening for uterine leiomyosarcoma. J Magn Reson Imaging. 2019; 49(7): e282-e294. doi: 10.1002/jmri.26630
12. Kubik-Huch RA, Weston M, Nougaret S, Leonhardt H, Thomassin-Naggara I, Horta M, et al. European Society of urogenital radiology (ESUR) guidelines: MR imaging of leiomyomas. Eur Radiol. 2018; 28: 3125-3137. doi: 10.1007/s00330-017-5157-5
13. Smith J, Zawaideh JP, Sahin H, Freeman S, Bolton H, Addley HC. Differentiating uterine sarcoma from leiomyoma: BET(1)T(2)ER Check! Br J Radiol. 2021; 94(1125): 20201332. doi: 10.1259/bjr.20201332
14. Reichert VMC, Alwafai Z, Zygmunt MT, Vollmer M, Köhler G. Accidental Morcellation of Uterine Leiomyosarcoma Influences Relapse Free Survival but Does Not Negatively Influence Overall Survival. J Clin Med. 2023; 12(2): 591. doi: 10.3390/jcm12020591
15. Sotomayor CG, Parra C, Miranda M, Casas JS, Cárdenas G, Sanhueza Á, et al. Hyaline and Cystic Degeneration of Uterine Leiomyomas: CT and MR Imaging with Histopathological Sample Analyses. Diagnostics (Basel). 2023; 13(20): 3230. doi: 10.3390/diagnostics13203230
16. El Graini S, Sassi S, El Haddad S, Rouas L, El Youssfi M. Lipoleiomyoma: a potential mimic of an ovarian dermoid cyst on MRI-a case report. J Surg Case Rep. 2024; 2024(2): rjae041. doi: 10.1093/jscr/rjae041
17. Al Khuri M, Al Salmi I, Al Ajmi H, Al Hadidi A, Alabousi A, Haider E, et al. Validating the diagnostic accuracy of an MRI-based scoring system for differentiating benign uterine leiomyomas from leiomyosarcomas. Int J Gynecol Cancer. 2024; 34(7): 1027-1033. doi: 10.1136/ijgc-2023-005220